Received Jul 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Joint pain; fever; diarrea; Runny nose; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of joint pain in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced joint pain (Verbatim: Joint pain), fever (Verbatim: fever), diarrhea (Verbatim: diarrea) and runny nose (Verbatim: Runny nose). The outcome of the joint pain, fever, diarrhea and runny nose were not reported. It was unknown if the reporter considered the joint pain, fever, diarrhea and runny nose to be related to Arexvy. It was unknown if the company considered the joint pain, fever, diarrhea and runny nose to be related to Arexvy. Additional Information: GSK Receipt Date:16-JUL-2025 This case was reported by a consumer via interactive digital media. The patient had taken vaccine and have experienced reaction joint pain, fever, diarrhea and runny nose.